Pancreatic cancer treatment device company OncoSil Medical Limited (ASX:OSL) is pleased to announce the first patient treatment in Germany using the OncoSil™ device.
The successful treatment was performed on 15 October 2025 at Universitätsklinikum Augsburg, a leading university hospital renowned for its excellence in oncology. This important milestone marks the commencement of OncoSil’s commercial activities in Germany, the largest and most influential healthcare market in Europe.
Germany represents a key strategic market for OncoSil Medical, given its advanced healthcare infrastructure, strong clinical expertise in oncology, and early adoption of innovative medical technologies. The Company will continue to collaborate closely with German physicians, healthcare institutions and health insurers to facilitate broader patient access to the OncoSil™ device.
Nigel Lange, CEO & Managing Director of OncoSil Medical, said:
"We are very proud to announce the first OncoSil™ treatment in Germany, a major milestone for the Company. This represents our initial commercial entry into the German market, which is one of Europe’s most important and sophisticated medical device markets.
From a broader European perspective, this initial OncoSil™ treatment in Germany is further evidence that our targeted penetration of key countries across the Continent is being delivered. We now look forward to working with leading German physicians to bring our innovative treatment to more pancreatic cancer patients over the months and years ahead."
About us:
About OncoSil Medical
OncoSil Medical Limited (ASX:OSL) has developed a cancer treatment device, the OncoSil™ brachytherapy device, which is a critical component of a revolutionary brachytherapy treatment for locally advanced unresectable pancreatic cancer. This type of cancer is the 12th most common cancer in men and the 11th most common cancer in women across the globe, with some 500,000 new cases of pancreatic cancer detected every year. With pancreatic cancer typically diagnosed at a later stage, it has a poor prognosis for longterm survival.
The OncoSil™ device delivers a targeted intratumoural placement of Phosphorous-32 (32P) in the treatment of locally advanced unresectable pancreatic cancer. This occurs via injection directly into a patient’s pancreatic tumours under endoscopic ultrasound guidance and takes place in combination with gemcitabine-based chemotherapy.
The OncoSil™ device that has already received breakthrough device designation in the European Union, United Kingdom and United States for the treatment of locally advanced unresectable pancreatic cancer in combination with chemotherapy. CE Marking has additionally been granted for the OncoSil™ device, which can be marketed in the European Union, United Kingdom.
While clinical trials involving the OncoSil™ device continue to occur, the Company is simultaneously moving to commercialise this unique medical technology. It is currently approved for sale in 30+ countries including European Union, United Kingdom, Türkiye and Israel, with initial commercial pancreatic cancer treatments using the device already undertaken in Spain, Italy and Israel.
To learn more, please visit: www.oncosil.com
Contact details:
For further information, please contact:
OncoSil Medical Limited
Nigel Lange
CEO & Managing Director
[email protected]
+49 16096424981
Company Secretary
Mr. Tim Luscombe
Joint Company Secretary
[email protected]
+61 429 707 079
Mr. David Wood
Joint Company Secretary
[email protected]
+61 408 393 670
Investor Relations
The Capital Network
Julia Maguire
+61 2 7257 7338
[email protected]